ADS Clinical Orals: GLP1/GIP
Tracks
Breakout 3: Meeting Room 1,2,3 combined
| Thursday, August 22, 2024 |
| 2:30 PM - 3:30 PM |
| Meeting Room 1,2,3 combined |
Speaker
Dr Ryan Jalleh
Research Fellow
Central Adelaide Local Health Network
Short-acting GLP-1RA Therapy attenuates the Counter-regulatory acceleration of Gastric emptying during Insulin-induced Hypoglycaemia in Type 2 Diabetes
2:30 PM - 2:45 PMBiography
Dr Ryan Jalleh is an endocrine consultant at the Northern Adelaide Local Area Network and the Mary Overton Research Fellow at Central Adelaide Local Health Network. He completed his PhD in March 2024 and is pursuing further research in incretin physiology.
Dr Paul Lidbury
Medical Writer
Envision Pharma Group
Analysis of Glucose Biomarkers in Phase I and Phase II Studies of Survodutide in People with Type 2 Diabetes or Living With Overweight/Obesity
2:45 PM - 3:00 PMBiography
Prof Elif Ekinci is a clinician researcher, an academic endocrinologist who is working to translate research into improved outcomes for people with T1D and T2D. Her research is focused on the pathophysiology, prevention, detection and treatment of diabetes and its complications through mechanistic studies, observational studies and clinical trials.
Prof Roger Chen
Professor
The University of Sydney / University of NSW / St Vincent's Hospital
Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta Cell Function and Insulin Sensitivity
3:00 PM - 3:15 PMBiography
Roger Chen is an endocrinologist at St Vincent’s Hospital, Sydney with interests in diabetes, diabetes and mental illness and transplant-related endocrine disorders.
Miss Amanda Purcell
PhD Candidate
Kolling Institute / University of Sydney
A Systematic review of Metabolic and Glycaemic outcomes in Patients with concurrent Overweight/ Obesity and Type 1 Diabetes following prolonged Glucagon-like Peptide-1 Receptor agonist treatment
3:15 PM - 3:30 PMBiography
Amanda Purcell is a PhD candidate at the University of Sydney investigating the use of incretin based therapies for individuals with type 1 diabetes and overweight/obesity.
Prof Michael Horowitz
Director, Endocrine and Metabolic Unit
The University of Adelaide
Chairperson
2:30 PM - 3:30 PMBiography
Dr Joey Kaye
Endocrinologist
Sir Charles Gairdner Hospital
Chairperson
2:30 PM - 3:30 PMBiography
